Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:CNTX NASDAQ:DTIL NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.36+3.5%$2.44$1.29▼$3.23$215.58M2.76283,109 shs330,901 shsCNTXContext Therapeutics$0.64-2.5%$1.74$0.55▼$3.62$60.06M1.754.06 million shs1.51 million shsDTILPrecision BioSciences$8.24+0.7%$7.14$3.53▼$8.82$211.06M1.25510,997 shs424,624 shsTNXPTonix Pharmaceuticals$12.71+3.0%$12.66$10.03▼$69.97$196.71M1.64543,649 shs188,640 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+3.51%+9.26%+12.38%+1.72%+32.58%CNTXContext Therapeutics-2.46%+10.48%-63.57%-75.66%-2.66%DTILPrecision BioSciences+0.73%+4.04%+26.77%+31.63%+88.34%TNXPTonix Pharmaceuticals+3.00%-0.31%+14.81%-2.75%-64.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.36+3.5%$2.44$1.29▼$3.23$215.58M2.76283,109 shs330,901 shsCNTXContext Therapeutics$0.64-2.5%$1.74$0.55▼$3.62$60.06M1.754.06 million shs1.51 million shsDTILPrecision BioSciences$8.24+0.7%$7.14$3.53▼$8.82$211.06M1.25510,997 shs424,624 shsTNXPTonix Pharmaceuticals$12.71+3.0%$12.66$10.03▼$69.97$196.71M1.64543,649 shs188,640 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+3.51%+9.26%+12.38%+1.72%+32.58%CNTXContext Therapeutics-2.46%+10.48%-63.57%-75.66%-2.66%DTILPrecision BioSciences+0.73%+4.04%+26.77%+31.63%+88.34%TNXPTonix Pharmaceuticals+3.00%-0.31%+14.81%-2.75%-64.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.80Moderate Buy$5.00111.86% UpsideCNTXContext Therapeutics 2.89Moderate Buy$6.17867.17% UpsideDTILPrecision BioSciences 2.60Moderate Buy$32.25291.38% UpsideTNXPTonix Pharmaceuticals 3.00Buy$24.0088.83% UpsideCurrent Analyst Ratings BreakdownLatest CNTX, DTIL, TNXP, and CGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026TNXPTonix Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$26.006/24/2026TNXPTonix Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.006/9/2026DTILPrecision BioSciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.005/27/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/21/2026CGENCompugen Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $5.005/8/2026DTILPrecision BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/5/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.004/20/2026CGENCompugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.76M3.07$0.39 per share6.10$1.09 per share2.17CNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/ADTILPrecision BioSciences$34.26M6.21N/AN/A$4.03 per share2.04TNXPTonix Pharmaceuticals$13.11M15.45N/AN/A$19.17 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.376.38N/AN/A47.97%47.72%27.51%8/5/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)DTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)TNXPTonix Pharmaceuticals-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)Latest CNTX, DTIL, TNXP, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07-$0.08-$0.01-$0.08$1.57 million$2.18 million5/11/2026Q1 2026TNXPTonix Pharmaceuticals-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.236.23CNTXContext TherapeuticsN/A8.968.96DTILPrecision BioSciences0.2914.0214.02TNXPTonix PharmaceuticalsN/A6.996.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%CNTXContext Therapeutics14.03%DTILPrecision BioSciences37.99%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%CNTXContext Therapeutics4.80%DTILPrecision BioSciences2.70%TNXPTonix Pharmaceuticals2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataTNXPTonix Pharmaceuticals5015.94 million15.62 millionNot OptionableCNTX, DTIL, TNXP, and CGEN HeadlinesRecent News About These CompaniesTonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, News, Quote & History - Yahoo FinanceJuly 2, 2026 | finance.yahoo.comTonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold RatingJune 29, 2026 | seekingalpha.comTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)June 29, 2026 | finance.yahoo.comTonix Pharma Begins Pivotal Phase 2 Depression TrialJune 29, 2026 | tipranks.comTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)June 29, 2026 | globenewswire.comThis Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayJune 25, 2026 | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Director Carolyn Taylor Purchases 1,415 SharesJune 16, 2026 | insidertrades.comWe're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn RateJune 13, 2026 | finance.yahoo.comTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11, 2026 | finance.yahoo.comTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11, 2026 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Newcomb Stillwell Purchases 5,000 SharesJune 10, 2026 | insidertrades.comWhy Is TNXP Stock Rising Today?June 8, 2026 | stocktwits.comSTonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYAJune 8, 2026 | benzinga.comTonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYAJune 8, 2026 | benzinga.comTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesJune 8, 2026 | finance.yahoo.comTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesJune 8, 2026 | globenewswire.comTonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor FocusJune 2, 2026 | tipranks.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical ...May 29, 2026 | markets.businessinsider.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 28, 2026 | finance.yahoo.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTX, DTIL, TNXP, and CGEN Company DescriptionsCompugen NASDAQ:CGEN$2.36 +0.08 (+3.51%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$2.37 +0.01 (+0.21%) As of 07/6/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Context Therapeutics NASDAQ:CNTX$0.64 -0.02 (-2.46%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$0.65 +0.01 (+2.26%) As of 07/6/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Precision BioSciences NASDAQ:DTIL$8.24 +0.06 (+0.73%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$8.24 0.00 (0.00%) As of 07/6/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Tonix Pharmaceuticals NASDAQ:TNXP$12.71 +0.37 (+3.00%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$12.64 -0.07 (-0.52%) As of 07/6/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
